Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma

Blood Cancer J. 2022 Jan 5;12(1):3. doi: 10.1038/s41408-021-00600-6.

Authors

Jean-Sébastien Claveau¹, Sophie Savary Bélanger², Imran Ahmad², Jean-Sébastien Delisle², Vincent De Guire³, Jean Roy², Richard LeBlanc²

Affiliations

¹ Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, Université de Montréal, Montreal, QC, Canada. [email protected].
² Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, Université de Montréal, Montreal, QC, Canada.
³ Department of Biochemistry, Maisonneuve-Rosemont Hospital, Université de Montréal, Montreal, QC, Canada.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Disease Management
Female
Humans
Immunoglobulin Heavy Chains / blood*
Immunoglobulin Light Chains / blood*
Male
Middle Aged
Multiple Myeloma / blood
Multiple Myeloma / therapy*
Progression-Free Survival
Prospective Studies

Substances

Immunoglobulin Heavy Chains
Immunoglobulin Light Chains